#LivingInnovation

Welcome to Pfizer EU Policy

We partner with EU policy-makers and other stakeholders, driven by our purpose: Breakthroughs that change patients’ lives.

Learn more about our team and vision to contribute to more pro-patient and pro-innovation policies in the EU. And don’t hesitate to follow @PfizerEUPolicy on Twitter!

Learn More

scroll-down

Ana Luzuriaga: Targeting Rare Diseases

Pfizer Spain Communication Manager fights for better understanding, treatments, and policy support for rare diseases

Learn more

Tobias Schulz: Health Data

Pfizer Germany Senior Manager, Policy and Public Affairs, built a career on making sure that health data is used in the best ways it can be for patients and society

Learn more

Bharati Shivalkar: Women at Heart

Pfizer’s BeLux Country Medical Director is passionate about fighting cardiovascular disease and empowering women

Learn more

Isabella Grueso: Beating Cancer

Pfizer’s Global Breast Cancer & Precision Medicine Policy Director grew up seeing the importance of Access to Medicines, and applies these lessons to breast cancer policy today

Learn more

Jo Atkinson: Fighting Resistant Infections

Pfizer’s Anti-Infectives Product Lead highlights the importance of R&D with a focus on AMR patients.

Learn more

Video

2:20 min

The EU Pharma Strategy: Pfizer's Vision

We are witnessing a once-in-a-generation legislative revision in Europe.

As a partner of the EU institutions, we aim to ensure that the Pharmaceutical Strategy for Europe delivers both for patients and for innovation. We believe these goals can and should be pursued in parallel.

Meet the Team

EU Register of Interest Representatives # 4263301811-33

@PfizerEUPolicy Jun 13

RT @sweden2023eu: #EPSCO | Ministers have adopted a recommendation for combating antimicrobial resistance. https://twitter.com/PfizerEUPolicy/status/1668567166914899969

@PfizerEUPolicy Jun 13

To revitalize anti-microbial R&D it is essential to reward successful innovation and attract needed investment. #AMR For instance, Transferable Exclusivity Vouchers (TEV) represent a unique solution within a broader package of measures. #EUPharmaStrategy #LivingInnovation https://t.co/hiSXna2E0H

@PfizerEUPolicy Jun 12

#AMR is a serious threat. To combat it, a predictable legislative framework that incentivises innovative R&D in new treatments and vaccines is essential. A key topic that will be discussed at the #EPSCO Council Meeting today and tomorrow. #LivingInnovation

@PfizerEUPolicy Jun 9

The importance of getting access to the right medicines is one key #LivingInnovation focus. However, the approach set out in the EU Pharma Legislation would do little to improve access, while negatively impacting innovation in Europe. @EFPIA See why: https://t.co/HnYEgjkFw2 https://t.co/uxgRKwsS7R

@PfizerEUPolicy Jun 8

Tackling #ClimateChange needs everyone. For instance, we plan to: 🌍 Source 80% of electricity from renewables by 2025 and 100% by 2030 🌍 Reduce GHG emissions from business travel 25% by 2025 from a 2019 baseline https://t.co/7fjOYIaLqg #LivingInnovation https://t.co/iC91g2zCUj

@PfizerEUPolicy Jun 7

Environmental #sustainability is a key value driver to enable transformational health innovation 💪 That's why working together on ‘extended’ Environmental Risk Assessments (ERAs) is of the utmost importance: https://t.co/EFUGprMsyE #LivingInnovation https://t.co/gqqoBttodd

@PfizerEUPolicy Jun 6

‘Extended’ Environmental Risk Assessments (ERAs) offer #sustainability advantages. Rather than assessing just one pharmaceutical (as is currently the case), an eERA looks at the combined risk of multiple products with the same ingredient. 👉 #EUPharmaStrategy #LivingInnovation https://t.co/aTVkEZ1kSB

@PfizerEUPolicy Jun 5

#EUGreenWeek is here 🌍🌏🌎 Every industry has environmental impacts, and pharma is no exception. That's why we're pushing for extended environmental risk assessments (eERA) for a more sustainable healthcare system. 👉 https://t.co/7fjOYIaLqg #LivingInnovation https://t.co/ZRqpnmSP93

@PfizerEUPolicy Jun 2

IP protection and strong incentives allow innovative medicines to get to patients. Existing IP protections and rewards remain essential to foster R&D, as explained by our #PfizerColleague Ana. #LivingInnovation #EUPharmaStrategy

@PfizerEUPolicy Jun 2

#PfizerColleague @aida_habtezion, Chief Medical Officer, is speaking today at #GSElevate2023. Working together to raise global dermatology patient voices is essential to improving access to effective treatments. @IADPO #LivingInnovation https://t.co/zCJU0V5EH1